Literature DB >> 30013666

Ecotropic viral integration site 1 regulates the progression of acute myeloid leukemia via MS4A3-mediated TGFβ/EMT signaling pathway.

Min Jiang1,2, Xueqin Zou3, Wenhua Huang1.   

Abstract

Acute myeloid leukemia (AML) is a type of malignant tumor that is caused by malignant clone hematopoietic stem cells. The ecotropic viral integration site 1 (Evi1) is a zinc finger transcription factor, which is highly expressed in AML, and its expression level has been associated with poor prognosis of AML. Previous studies have indicated that Evi1 may regulate cell proliferation, differentiation and apoptosis by inhibiting the membrane-spanning-4-domains subfamily-A member-3 (MS4A3) gene in AML. The aim of the present study was to investigate the role of Evi1 in the progression of AML. The results revealed that Evi1 was overexpressed in leukemia cells compared with normal T lymphocytes. MicroRNAs (miR)-133 and -431 that target Evi1 were investigated, and it was observed that there was a low expression of miR-431 in AML. The transfection of miR-431 was able to decrease the promoter methylation levels of the Evi1 gene in AML cells. The transfection of miR-431 also suppressed the migration and invasion of AML cells. The present study revealed that the transfection of miR-431 mimic was able to downregulate MS4A3 expression in AML cells. Furthermore, the expression levels of transforming growth factor β (TGFβ) and epithelial-to-mesenchymal transition (EMT) markers fibronectin, α-smooth muscle actin, and vimentin were downregulated following the transfection of miR-431 in AML cells. The overexpression of MS4A3 was also able to suppress miR-431-mediated inhibition of the expression of TGFβ and EMT markers in AML cells. The addition of TGFβ inhibited the downregulation of EMT markers by transfection of miR-431 in AML cells. The transfection of miR-431 suppressed the migration and invasion of AML cells, which was also abolished by the addition of TGFβ. In conclusion, the results of the present study indicated that Evi1 may be a potential molecular target of leukemia therapy via MS4A3-mediated TGFβ/EMT signaling pathway.

Entities:  

Keywords:  acute myeloid leukemia; ecotropic viral integration site 1; epithelial-to-mesenchymal transition; membrane-spanning-4-domains subfamily-A member-3; microRNA-431; transforming growth factor β

Year:  2018        PMID: 30013666      PMCID: PMC6036571          DOI: 10.3892/ol.2018.8890

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  29 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.

Authors:  Iria Vázquez; Miren Maicas; José Cervera; Xabier Agirre; Oskar Marin-Béjar; Nerea Marcotegui; Carmen Vicente; Idoya Lahortiga; Maria Gomez-Benito; Claudia Carranza; Ana Valencia; Salut Brunet; Eva Lumbreras; Felipe Prosper; María T Gómez-Casares; Jesús M Hernández-Rivas; María J Calasanz; Miguel A Sanz; Jorge Sierra; María D Odero
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

3.  Improved classification of MLL-AF9-positive acute myeloid leukemia patients based on BRE and EVI1 expression.

Authors:  Sylvie M Noordermeer; Davide Monteferrario; Mathijs A Sanders; Lars Bullinger; Joop H Jansen; Bert A van der Reijden
Journal:  Blood       Date:  2012-05-03       Impact factor: 22.113

4.  Acute Myeloid Leukemia After Radium-223 Therapy: Case Report.

Authors:  Andreas Varkaris; Krishna Gunturu; Tarun Kewalramani; Christopher Tretter
Journal:  Clin Genitourin Cancer       Date:  2016-12-01       Impact factor: 2.872

5.  Gene mutations in acute myeloid leukemia.

Authors:  Hiroki Yamaguchi
Journal:  Rinsho Ketsueki       Date:  2016

6.  The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50.

Authors:  Tomoyuki Uchida; Masao Hagihara; Jian Hua; Morihiro Inoue
Journal:  Leuk Res       Date:  2016-11-25       Impact factor: 3.156

7.  High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.

Authors:  Stefan Gröschel; Sanne Lugthart; Richard F Schlenk; Peter J M Valk; Karina Eiwen; Chantal Goudswaard; Wim J L van Putten; Sabine Kayser; Leo F Verdonck; Michael Lübbert; Gert-Jan Ossenkoppele; Ulrich Germing; Ingo Schmidt-Wolf; Brigitte Schlegelberger; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Bob Löwenberg; Konstanze Döhner; Ruud Delwel
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

8.  EVI1 targets ΔNp63 and upregulates the cyclin dependent kinase inhibitor p21 independent of p53 to delay cell cycle progression and cell proliferation in colon cancer cells.

Authors:  Kasturi Bala Nayak; Nivedita Kuila; Alok Das Mohapatra; Aditya K Panda; Soumen Chakraborty
Journal:  Int J Biochem Cell Biol       Date:  2013-05-09       Impact factor: 5.085

9.  Tetraploidy/near-tetraploidy acute myeloid leukemia.

Authors:  Lanshan Huang; Sa A Wang; Courtney DiNardo; Shaoying Li; Shimin Hu; Jie Xu; Wenli Zhou; Maitrayee Goswami; L Jeffrey Medeiros; Guilin Tang
Journal:  Leuk Res       Date:  2016-12-02       Impact factor: 3.156

10.  Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction.

Authors:  Xuetian Yue; Yuhan Zhao; Cen Zhang; Jun Li; Zhen Liu; Juan Liu; Wenwei Hu
Journal:  Oncotarget       Date:  2016-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.